Autopsy report · NCT00052884

Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation

“Slow accrual and changes in clinical practice”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 7 years 2 months before it stopped.
• 8 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Eastern Cooperative Oncology Group

Sponsor type

University, hospital or other

Conditions

Drug/Agent Toxicity by Tissue/Organ; Multiple Myeloma and Plasma Cell Neoplasm

Interventions

filgrastim; amifostine trihydrate; melphalan; bone marrow ablation with stem cell support; peripheral blood stem cell transplantation

Participants

8

Sites

16

Countries

United States

Trials that died the same way

• Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant
  “Due to slow accrual of patients” (81% match in meaning)
• Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
  “slow accrual - the 1 patient accrued did not go on treatment” (67% match in meaning)
• Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy
  “lack of patient population - slow accrual” (67% match in meaning)
• Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
  “Slow accrual 5 patients out of 25 expected. Primary objectives could not be met without recruiting more patients.” (65% match in meaning)
• A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma
  “Changes in treatment paradigm resulted in a lower than expected rate of accrual.” (65% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.